ILF roundtable
Rapid access to new technology and reaching the unreached

Tuesday, 24 July 2018, 18:00 – 21:30
Room F002-004, RAI Amsterdam, the Netherlands
Today’s topic

Accelerating access to new diagnostic technologies

In line with UNAIDS 90-90-90 targets, by 2020, 90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy (ART), and 90% of all people receiving ART will achieve viral suppression.

Diagnostic tests are essential to achieve these targets: they form the basis for accurate diagnosis and management of HIV disease and related opportunistic infections. However, many questions remain regarding the optimal pathways for diagnostic test approval, monitoring schema, and equity in global access.

This roundtable will stimulate multi-stakeholder discussions to address the questions:
• What can be done to speed the pathways to diagnostic test approval?
• How do we reach equity in access to state of the art diagnostics?
Today’s objectives

• Review important issues around access to diagnostics

• Provide a multi-stakeholder platform for exchange on challenges and solutions to ensure rapid and equitable access to new diagnostic technologies

• Develop a statement on approaches to expedite access to proven - both analytically and in terms of impact – diagnostic technologies.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30 – 18:35</td>
<td>Welcome and opening remarks: Rapid access to new technology and reaching the unreached</td>
</tr>
<tr>
<td></td>
<td><em>Co-chairs: Ken Mayer (The Fenway Institute, IAS Governing Council) &amp; Duncan Blair (Abbott)</em></td>
</tr>
<tr>
<td>18:35 – 18:45</td>
<td>Time, money, opportunity cost, risks and decision-making: What is innovation?</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Philippe Jacon (MedTech Europe)</em></td>
</tr>
<tr>
<td>18:45 – 18:55</td>
<td>Piloting, measuring impact and scaling up innovation: What are the barriers?</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Jennifer Cohn (EGPAF)</em></td>
</tr>
<tr>
<td>18:55 – 19:05</td>
<td>Global health and impact on individual people’s life: What does delayed access really mean?</td>
</tr>
<tr>
<td></td>
<td><em>Speaker: Solange Baptiste (ITPC)</em></td>
</tr>
<tr>
<td>19:05 – 19:30</td>
<td>Break</td>
</tr>
<tr>
<td>19:30 – 20:10</td>
<td>Open-floor discussion I: What can be done to speed the pathways to diagnostic test approval and implementation?</td>
</tr>
<tr>
<td></td>
<td><em>Facilitator: George Siberry (S/GAC)</em></td>
</tr>
<tr>
<td>20:10 – 20:50</td>
<td>Open-floor discussion II: How do we reach equity in access to state of the art diagnostics?</td>
</tr>
<tr>
<td></td>
<td><em>Facilitator: Catharina Boehme (FIND)</em></td>
</tr>
<tr>
<td>20:50 – 21:00</td>
<td>Summary and closing comments: Approaches to expedite access to proven diagnostic technologies</td>
</tr>
<tr>
<td></td>
<td><em>Co-chairs: Ken Mayer (The Fenway Institute, IAS Governing Council) &amp; Duncan Blair (Abbott)</em></td>
</tr>
<tr>
<td>21:00 – 21:30</td>
<td>Networking reception for continued discussion</td>
</tr>
</tbody>
</table>
The ILF thanks its corporate partners for the support

ILF Corporate Partners 2018

**GOLD PARTNERS**

- Gilead
- Janssen
- MSD
- ViiV Healthcare

**SILVER PARTNERS**

- Abbott

**BRONZE PARTNERS**

- Beckman Coulter
- Cepheid
- Cipla
- Coral
- LUPIN
- Roche
- Sysmex
Key considerations: Compliance with competition rules

What to avoid

- Do not discuss with other participants competitively sensitive information on anything relating to topics such as prices, discounts, margins, price-related contractual terms or territorial protection.
- Do not exchange information on costs, capacity, business plans or commercial strategy. The only exception is for industry data that are publicly available via data services, such as interest rates.
- Do not exchange individualized information on output plans.
- Do not engage in conduct that could have the effect of restricting competition by excluding actual or potential competitors from the market or preventing them from competing effectively.
- Do not discuss matters relating to your company’s marketing plans, design, production or distribution.
- Do not share with other participants any other competitively sensitive or confidential information.

What to do

- Do report to the IAS any discussion or conduct that you suspect might violate these guidelines, and keep a copy of such correspondence.
- Do leave any discussion that you feel might infringe these guidelines, and ask for your leaving to be recorded in the minutes.
- Do refuse any commercially sensitive or confidential information you might be offered. If you receive such information, return them immediately, emphasizing that you do not want to have access to them. Keep a copy of such correspondence.
- Do remember that you are responsible for your own compliance with these guidelines.
Creating a safe space for discussion

• Active participation

• Neutral analysis

• Constructive comments
Housekeeping instructions

• Introduce yourself (name, affiliation) before speaking

• Speak through the microphone